Grants per year
Grants 2011 2022
- 1 - 25 out of 38 results
- Status, start date (descending)
Active
Effects of a D1PAM on Novel Object Recognition, Social Interaction, Brain Neurotransmitter Release and markers for Synaptic Plasticity in Adult and Aged hD1Kl mice
11/19/19 → 11/19/21
Project: Research project
Neuronal Plasticity
Interpersonal Relations
Neurotransmitter Agents
Brain
Rivastigmine
Prot #SCZD-0001: A Pilot Study of Digital Health Technology Assessments in Schizophrenia
PRA Health Sciences, Millennium Pharmaceuticals, Inc
2/13/19 → 2/13/22
Project: Research project
Cognition
Control Groups
Prot #SNR-05: An Adaptive, Phase II/III, Double-Blind, Randomized, Placebo-Controlled, Two-Part, Dose-Finding, Multi-Center Study of the Safety and Efficacy of NaBen® (Sodium Benzoate), a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy with Clozapine
Meltzer, H. Y. & Meriden, Z.
Amarex Clinical Research, SyneuRx International (Taiwan) Corp.
3/14/18 → 3/14/21
Project: Research project
Development of transdiagnostic genetic markers to predict suicide attempt
Li, J. & Meltzer, H. Y.
American Foundation for Suicide Prevention
11/1/17 → 10/31/19
Project: Research project
Genetic Markers
Suicide
Biomarkers
Triage
Major Depressive Disorder
Prot #ACP-103-035: A 52-Week, Open-Label, Extension Study of Pimavanserin for the Adjunctive Treatment of Schizophrenia
Meriden, Z., Meltzer, H. Y. & Rado, J. T.
Quintiles, Inc., ACADIA Pharmaceuticals Inc.
9/12/17 → 9/12/20
Project: Research project
Evaluate Pimavanserin, Risperidone or a combination of Pimavanserin and Risperidone in a treatment-resistant model of negative symptoms of schizophrenia
2/10/17 → 2/10/20
Project: Research project
Risperidone
Antipsychotic Agents
Schizophrenia
Interpersonal Relations
Psychopathology
Rapastinel Mechanism of Action and Effects on Cognitive Function
9/1/16 → 11/22/19
Project: Research project
Ketamine
Cognition
pamidronate
Antidepressive Agents
Phencyclidine
LiveWell: A Mobile Intervention for Bipolar Disorder
Dopke, C. A., Dopke, C. A., Goulding, E. H., Kording, K. P., Kording, K. P., Kwasny, M. J., Kwasny, M. J., Liu, L., Liu, L., Meltzer, H. Y., Meltzer, H. Y., Mohr, D. C. & Mohr, D. C.
National Institute of Mental Health
7/15/16 → 6/30/20
Project: Research project
Bipolar Disorder
Databases
Self Care
Self Report
Phenotype
Age-Related Histone Modification Effect on Antipsychotic Action
Chan, S., Csernansky, J. G., Dong, H., Fang, D. & Meltzer, H. Y.
National Institute of Mental Health
5/26/16 → 2/28/21
Project: Research project
Histone Code
Antipsychotic Agents
Histone Deacetylase Inhibitors
Drug-Related Side Effects and Adverse Reactions
Epigenomics
Finished
Studies to Investigate the Mechanism of Action of Sunovion Compound SEP-856
4/26/18 → 4/26/19
Project: Research project
Antipsychotic Agents
Psychotic Disorders
Serotonin 5-HT2 Receptor Agonists
Receptor, Serotonin, 5-HT2A
Risperidone
Prot #BIO-17-1142: Contribution of dopamine D3 receptor partial agonism of cariprazine to improve cognition and psychosis
4/15/17 → 4/15/18
Project: Research project
Dopamine D3 Receptors
Psychotic Disorders
Cognition
Antipsychotic Agents
Microdialysis
Validation of a pharmacogenomic panel predicting improvement in psychopathology to atypical antipsychotic drugs
Li, J. & Meltzer, H. Y.
11/10/16 → 11/10/17
Project: Research project
Effect of valbenazine, a vesicular monoamine transporter (VMAT2) inhibitor, on neurotransmitter efflux in the medial prefrontal cortex and dorsal striatum of mice
9/26/16 → 9/26/19
Project: Research project
Vesicular Monoamine Transport Proteins
Prefrontal Cortex
Neurotransmitter Agents
Antipsychotic Agents
valbenazine
Improving Outcomes in Schizophrenia Through Identification of Genetic Risk Factors
Li, J. & Meltzer, H. Y.
Clinical Reference Laboratory, Inc.
3/23/16 → 3/23/17
Project: Research project
Vortioxetine as a Potential Enhancer of Cognition in Schizophrenia
Takeda Pharmaceuticals U.S.A., Inc.
3/17/16 → 3/17/18
Project: Research project
Cognition
Schizophrenia
Antipsychotic Agents
Phencyclidine Receptors
Reversal Learning
Prot #1289.6: A phase II randomised, double-blinded, placebo-controlled study to evaluate the efficacy, safety, and tolerability of four orally administrated doses of BI 409306 during a 12-week treatment period in patients with schizophrenia on stable ant
DrugDev Inc., Boehringer Ingelheim Pharmaceuticals, Inc.
1/29/15 → 1/29/18
Project: Research project
Identifying genetic basis for suicide prevention by clozapine: the EGF-MAPK-ERK signaling pathway
Li, J. & Meltzer, H. Y.
American Foundation for Suicide Prevention
10/1/14 → 4/30/17
Project: Research project
MAP Kinase Signaling System
Clozapine
Epidermal Growth Factor
Suicide
Genome-Wide Association Study
Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
9/15/14 → 9/15/17
Project: Research project
Effect of Magnesium Threonate (MgT) on Cognitive Enhancement in Schizophrenia
8/18/14 → 8/18/17
Project: Research project